NEW YORK and BASEL, Switzerland, Dec. 19, 2018 /PRNewswire/ — Roivant Sciences today announced that it has entered into a collaboration with Daiichi Sankyo Company, Limited (hereafter, Daiichi Sankyo) to facilitate the out-licensing of investigational medicines. Under the terms of the agreement, Roivant will have the option to obtain exclusive licenses for certain development programs from Daiichi Sankyo on prespecified terms contingent on phase of development.
Daiichi Sankyo has a wide range of compounds in development. Medicines that Roivant opts to license will be developed by new subsidiary companies within the Roivant family.
“It has been an honor and a pleasure for us to work with the entire Daiichi Sankyo team in the course of creating this partnership. I hope this can be a model for platform collaborations between Roivant and other innovative biopharmaceutical companies in the future,” said Dr. Mayukh Sukhatme, President of Roivant Pharma. “We look forward to accelerating the development of promising medicines from the impressive R&D engine at Daiichi Sankyo in the months and years ahead.”
About Roivant Sciences
Roivant aims to improve health by rapidly delivering innovative medicines and technologies to patients. We do this by building Vants – nimble, entrepreneurial biotech and healthcare technology companies with a unique approach to sourcing talent, aligning incentives, and deploying technology to drive greater efficiency in R&D and commercialization.
For more information, please visit www.roivant.com.
About Daiichi Sankyo
Daiichi Sankyo Group is dedicated to the creation and supply of innovative pharmaceutical products to address diversified, unmet medical needs of patients in both mature and emerging markets. With over 100 years of scientific expertise and a presence in more than 20 countries, Daiichi Sankyo and its 15,000 employees around the world draw upon a rich legacy of innovation and a robust pipeline of promising new medicines to help people. In addition to a strong portfolio of medicines for hypertension and thrombotic disorders, under the Group’s 2025 Vision to become a “Global Pharma Innovator with Competitive Advantage in Oncology,” Daiichi Sankyo research and development is primarily focused on bringing forth novel therapies in oncology, including immuno-oncology, with additional focus on new horizon areas, such as pain management, neurodegenerative diseases, heart and kidney diseases, and other rare diseases. For more information, please visit: www.daiichisankyo.com.
Head of Communications
SOURCE Roivant Sciences